CureVac N.V [CVAC] vs Dyne Therapeutics [DYN] Detailed Stock Comparison
CureVac N.V
NASDAQ
Loading...
Dyne Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: CureVac N.V wins in 10 metrics, Dyne Therapeutics wins in 5 metrics, with 0 ties. CureVac N.V appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | CureVac N.V | Dyne Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 5.40 | -3.88 | Dyne Therapeutics |
| Price-to-Book Ratio | 2.09 | 2.61 | CureVac N.V |
| Debt-to-Equity Ratio | 6.15 | 21.19 | CureVac N.V |
| PEG Ratio | -0.29 | -0.10 | CureVac N.V |
| EV/EBITDA | 3.50 | -2.95 | Dyne Therapeutics |
| Profit Margin (TTM) | 37.93% | 0.00% | CureVac N.V |
| Operating Margin (TTM) | -4,959.44% | 0.00% | Dyne Therapeutics |
| Return on Equity | 40.22% | -61.32% | CureVac N.V |
| Return on Assets (TTM) | 23.77% | -35.45% | CureVac N.V |
| Free Cash Flow (TTM) | $97.90M | $-294.75M | CureVac N.V |
| 1-Year Return | 85.91% | -62.43% | CureVac N.V |
| Price-to-Sales Ratio (TTM) | 2.40 | N/A | N/A |
| Enterprise Value | $1.02B | $1.30B | Dyne Therapeutics |
| EV/Revenue Ratio | 1.71 | N/A | N/A |
| Gross Profit Margin (TTM) | -77.75% | N/A | N/A |
| Revenue per Share (TTM) | $2 | $0 | CureVac N.V |
| Earnings per Share (Diluted) | $1.01 | $-3.88 | CureVac N.V |
| Beta (Stock Volatility) | 2.51 | 1.08 | Dyne Therapeutics |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
CureVac N.V vs Dyne Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| CureVac N.V | -0.73% | 1.12% | 1.12% | 0.00% | 104.15% | 56.81% |
| Dyne Therapeutics | -3.14% | 2.26% | -4.89% | 54.65% | 68.89% | -50.31% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| CureVac N.V | 85.91% | -28.06% | -89.68% | -90.32% | -90.32% | -90.32% |
| Dyne Therapeutics | -62.43% | -4.09% | -27.38% | -44.52% | -44.52% | -44.52% |
News Based Sentiment: CureVac N.V vs Dyne Therapeutics
CureVac N.V
News based Sentiment: POSITIVE
October was a pivotal month for CureVac, shifting the investment narrative from financial distress to a potential acquisition by BioNTech and a substantial patent settlement. While the initial financial results were disappointing, the acquisition offer and settlement significantly alter the risk-reward profile, making it a game-changing development for the company and its investors.
Dyne Therapeutics
News based Sentiment: POSITIVE
October was a strong month for Dyne Therapeutics, highlighted by key regulatory approvals (FDA Breakthrough Therapy and Japanese Orphan Drug designation) for DYNE-251, coupled with positive analyst upgrades and insider buying activity. While the company remains pre-revenue, these developments signal significant progress and potential for future growth, making it a noteworthy investment story.
Performance & Financial Health Analysis: CureVac N.V vs Dyne Therapeutics
| Metric | CVAC | DYN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.23B | $1.95B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 392,450 | 2,426,520 |
| 90 Day Avg. Volume | 441,167 | 2,473,740 |
| Last Close | $5.41 | $12.65 |
| 52 Week Range | $2.37 - $5.72 | $6.36 - $35.90 |
| % from 52W High | -5.42% | -64.76% |
| All-Time High | $151.80 (Dec 07, 2020) | $47.45 (Aug 19, 2024) |
| % from All-Time High | -96.44% | -73.34% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.91% | N/A |
| Quarterly Earnings Growth | -0.91% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.38% | 0.00% |
| Operating Margin (TTM) | -49.59% | 0.00% |
| Return on Equity (TTM) | 0.40% | -0.61% |
| Debt to Equity (MRQ) | 6.15 | 21.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.60 | $5.00 |
| Cash per Share (MRQ) | $1.74 | $4.81 |
| Operating Cash Flow (TTM) | $239.53M | $-359,560,000 |
| Levered Free Cash Flow (TTM) | $167.78M | $-222,398,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: CureVac N.V vs Dyne Therapeutics
| Metric | CVAC | DYN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 5.40 | -3.88 |
| Forward P/E | -12.39 | -4.13 |
| PEG Ratio | -0.29 | -0.10 |
| Price to Sales (TTM) | 2.40 | N/A |
| Price to Book (MRQ) | 2.09 | 2.61 |
| Market Capitalization | ||
| Market Capitalization | $1.23B | $1.95B |
| Enterprise Value | $1.02B | $1.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.71 | N/A |
| Enterprise to EBITDA | 3.50 | -2.95 |
| Risk & Other Metrics | ||
| Beta | 2.51 | 1.08 |
| Book Value per Share (MRQ) | $2.60 | $5.00 |
Financial Statements Comparison: CureVac N.V vs Dyne Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CVAC | DYN |
|---|---|---|
| Revenue/Sales | $1.46M | $0 |
| Cost of Goods Sold | $2.60M | N/A |
| Gross Profit | $-1.14M | N/A |
| Research & Development | $40.94M | $99.24M |
| Operating Income (EBIT) | $-72.47M | $-115.79M |
| EBITDA | $-64.55M | $-110.26M |
| Pre-Tax Income | $-70.38M | $-110.86M |
| Income Tax | $-476,526 | N/A |
| Net Income (Profit) | $-69.91M | $-110.86M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CVAC | DYN |
|---|---|---|
| Cash & Equivalents | $460.92M | $472.26M |
| Total Current Assets | $492.70M | $689.50M |
| Total Current Liabilities | $79.83M | $33.88M |
| Long-Term Debt | $36.56M | $18.22M |
| Total Shareholders Equity | $688.22M | $668.97M |
| Retained Earnings | $-1.78B | $-1.07B |
| Property, Plant & Equipment | $279.83M | $34.19M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CVAC | DYN |
|---|---|---|
| Operating Cash Flow | $-61.75M | $-110.37M |
| Capital Expenditures | $-855,634 | $-981,000 |
| Free Cash Flow | $-51.19M | $-106.87M |
| Debt Repayment | $-1.54M | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CVAC | DYN |
|---|---|---|
| Shares Short | 1.18M | 15.30M |
| Short Ratio | 2.41 | 6.78 |
| Short % of Float | 0.01% | 0.12% |
| Average Daily Volume (10 Day) | 392,450 | 2,426,520 |
| Average Daily Volume (90 Day) | 441,167 | 2,473,740 |
| Shares Outstanding | 263.31M | 102.32M |
| Float Shares | 125.87M | 122.63M |
| % Held by Insiders | 0.57% | 0.00% |
| % Held by Institutions | 0.07% | 0.95% |
Dividend Analysis & Yield Comparison: CureVac N.V vs Dyne Therapeutics
| Metric | CVAC | DYN |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |